Alar Pharmaceuticals Inc.
Taipei Exchange 6785.TWO
Alar Pharmaceuticals Inc. Revenue for the year ending December 31, 2023: USD 15.29 M
Alar Pharmaceuticals Inc. Revenue is USD 15.29 M for the year ending December 31, 2023, a 58,474.48% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
-
Alar Pharmaceuticals Inc. Revenue for the year ending December 31, 2022 was USD 26.10 K, a 0.00% change year over year.
-
Alar Pharmaceuticals Inc. Revenue for the year ending December 31, 2021 was USD 0.00, a -100.00% change year over year.
-
Alar Pharmaceuticals Inc. Revenue for the year ending December 31, 2020 was USD 21.33 K, a 0.00% change year over year.
-
Alar Pharmaceuticals Inc. Revenue for the year ending December 31, 2019 was USD 0.00.
Key data
| Date | Revenue | Gross Profit | Operating Income | EBIT |
|---|
Market news
Loading...
Taipei Exchange: 6785.TWO
| CEO | Dr. Yung-Shun Wen Ph.D. |
| IPO Date | Oct. 5, 2020 |
| Location | |
| Headquarters | No. 32, Keya Road |
| Employees | 22 |
| Sector | Health Care |
| Industries | |
Description
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson's disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email